デフォルト表紙
市場調査レポート
商品コード
1413939

ACE阻害剤の世界市場レポート 2024年

ACE Inhibitors Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
ACE阻害剤の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

ACE阻害剤市場規模は近年着実に成長しています。2023年の69億米ドルから2024年には72億4,000万米ドルへと、CAGR4.9%で成長します。過去数年間に観察された成長は、様々な要因によるものです。これには、心血管疾患の罹患率の上昇、高齢化人口の増加、医療介入の臨床的有効性と安全性プロファイル、糖尿病の流行、規制当局の承認とガイドラインの影響などが含まれます。

ACE阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.6%で90億米ドルに成長します。予測期間中に予想される成長はいくつかの要因に関連しており、特に心血管疾患の世界の負担の増大、高血圧治療ガイドラインの適用範囲の拡大、併用療法の進歩、心不全管理への重点化、ヘルスケアに対する認識とアクセスの改善などが挙げられます。予測期間中に予想される主な動向としては、腎臓保護への重点化、レニン・アンジオテンシン系阻害薬への嗜好性、ジェネリック医薬品競合と価格圧力に伴う課題、ヘルスケアにおける患者中心のアプローチへの移行、規制の更新と安全性への配慮の影響などが挙げられます。

高血圧症の有病率の高まりは、ACE阻害剤市場の成長を牽引する極めて重要な役割を果たすと予想されます。高血圧症は、血管内の圧力上昇を特徴とします。ACE阻害剤は、アンジオテンシン変換酵素阻害剤のカテゴリーに属し、高血圧の治療と管理に使用される一群の薬剤を表しています。これらの薬剤は血管を弛緩させ、血圧の低下と血流量の増加をもたらします。2023年3月現在、世界保健機関(WHO)の報告によると、高血圧に罹患している30~79歳の成人は世界で推定12億8,000万人であり、その3分の2は低・中所得国に居住しています。過去30年間で、30歳から79歳の高血圧患者は6億5,000万人と大幅に増加しています。驚くべきことに、成人の高血圧患者の約46%が、診断不足のために自分の状態に気づいていないです。この高血圧患者の急増は、ACE阻害剤市場の成長を促進する重要な要因となっています。

心臓疾患の罹患率の上昇も、ACE阻害剤市場の拡大に寄与すると期待される重要な要因です。心臓疾患には、冠動脈疾患、心不全、不整脈など、心臓や血管に影響を及ぼすさまざまな病状が含まれます。ACE阻害剤は、アンジオテンシン変換酵素を阻害することで、血管収縮、ナトリウム貯留、アルドステロン分泌を減少させ、最終的に心機能を改善することにより、心疾患の管理に重要な役割を果たしています。例えば、2023年5月、米国疾病予防管理センターは、2021年の冠動脈疾患(CAD)による死亡者数は375,476人であり、20歳以上の成人の約20人に1人がCADに罹患していると報告しました。注目すべきは、CADによる死亡の約10人に2人が65歳未満の成人で発生していることです。このように、心臓疾患の罹患率の増加は、ACE阻害剤市場の成長の実質的な促進要因となっています。

2023年のACE阻害剤市場で最大の地域は北米でした。アジア太平洋は、予測期間中にACE阻害剤世界市場レポートにおいて最も急成長する地域となる見込みです。ACE阻害剤市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のACE阻害剤市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • スルフヒドリル含有剤
  • ジカルボン酸塩含有剤
  • ホスホン酸塩含有薬剤
  • 世界のACE阻害剤市場、薬物別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ラミプリル
  • エナラプリル
  • ベナゼプリル
  • フォシノプリル
  • カプトプリル
  • モエキシプリル
  • その他の薬
  • 世界のACE阻害剤市場、剤形別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口錠剤
  • 経口ソリューション
  • 世界のACE阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 心不全
  • 慢性腎臓病
  • 高血圧
  • 糖尿病
  • 心臓発作
  • その他の用途
  • 世界のACE阻害剤市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • オンラインドラッグストア
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のACE阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のACE阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ACE阻害剤市場の競合情勢
  • ACE阻害剤市場の企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • Johnson &Johnson Private Limited
    • Merck KGaA
    • Sanofi SA

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11449

“ACE Inhibitors Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ace inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ace inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The ace inhibitors market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Sulfhydryl-containing Agents; Dicarboxylate-containing Agents; Phosphonate-containing Agents
  • 2) By Drug: Ramipril; Enalapril; Benazepril; Fosinopril; Captopril; Moexipril; Other Drugs
  • 3) By Dosage Form: Oral Tablets; Oral Solutions
  • 4) By Application: Heart Failure; Chronic Kidney Disease; Hypertension; Diabetes; Heart Attack; Other Applications
  • 5) By End-Users: Hospitals; Online Drug Stores; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Novartis Gohonzon & Johnson Private Limited; Merck Gaisano S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

ACE inhibitors, or angiotensin-converting enzyme inhibitors, constitute a class of medications utilized for the treatment and management of hypertension. Their mechanism of action involves the inhibition of the body's production of angiotensin II, a chemical responsible for constricting blood vessels and raising blood pressure. The primary purpose of ACE inhibitors is to induce relaxation in veins and arteries, ultimately leading to a reduction in blood pressure.

The main categories of ACE inhibitors encompass sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their structure. Various drugs fall into this category, including ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. These medications are available in diverse dosage forms, such as oral tablets and oral solutions. They find application in the treatment of various conditions, including heart failure, chronic kidney disease, hypertension, diabetes, and heart attacks. These medications are utilized by a range of end-users, including hospitals and online drug stores.

The countries covered in the ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The ace inhibitors market size has grown steadily in recent years. It will grow from $6.9 billion in 2023 to $7.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The observed growth in the historical period can be attributed to various factors. These include the heightened incidence of cardiovascular diseases, a growing aging population, the clinical effectiveness, and safety profile of medical interventions, the prevalence of diabetes, and the influence of regulatory endorsements and guidelines.

The ace inhibitors market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. The expected growth in the forecast period is linked to several factors, notably the escalating global burden of cardiovascular diseases, the broadening scope of hypertension treatment guidelines, advancements in combination therapies, an increased focus on heart failure management, and improved awareness and access to healthcare. Key trends anticipated in the forecast period encompass a heightened emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, challenges associated with generic competition and pricing pressures, a shift toward patient-centric approaches in healthcare, and the influence of regulatory updates and safety considerations.

The escalating prevalence of hypertension disorders is anticipated to play a pivotal role in driving the growth of the ACE inhibitors market. Hypertension, or high blood pressure, is characterized by elevated pressure within the blood vessels. ACE inhibitors, belonging to the category of angiotensin-converting enzyme inhibitors, represent a group of medications employed for the treatment and management of hypertension. These medications operate by relaxing blood vessels, leading to a reduction in blood pressure and an enhancement in blood flow. As of March 2023, the World Health Organization reported that an estimated 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, with two-thirds of these individuals residing in low- and middle-income nations. Over the past three decades, there has been a substantial increase of 650 million people aged 30 to 79 with hypertension. Alarmingly, around 46% of adults with hypertension are unaware of their condition due to a lack of diagnosis. This surge in hypertension cases stands as a significant factor propelling the growth of the ACE inhibitors market.

The rising incidence of cardiac disorders is another critical factor expected to contribute to the expansion of the ACE inhibitors market. Cardiac disorders encompass a range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a crucial role in managing cardiac disorders by inhibiting the angiotensin-converting enzyme, resulting in reduced vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving cardiac function. For instance, in May 2023, the Centers for Disease Control and Prevention reported that coronary artery disease (CAD) was responsible for 375,476 deaths in 2021, with approximately 1 in 20 adults aged 20 and older being affected by CAD. Notably, about 2 in 10 deaths from CAD occurred in adults less than 65 years old. The increasing incidence of cardiac disorders is thus a substantial driver behind the growth of the ACE inhibitors market.

A notable trend with a strong emphasis on product innovations, as major companies strategically develop novel products to strengthen their market positions and gain a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, achieved FDA approval for FILSPARI (sparsentan). This groundbreaking non-immunosuppressive therapy is intended for use in patients with IgA nephropathy (IgAN). FILSPARI represents a significant advancement as the only approved non-immunosuppressive therapy. It is an oral medication designed for once-daily use by adults with primary IgAN who are at risk of rapid disease progression, typically presenting with a UPCR of less than 1.5 g/g and proteinuria. This approval marks a noteworthy milestone in treatment options for IgAN, supplementing traditional approaches involving systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs).

Major players in the ACE inhibitors market are further intensifying their efforts to introduce innovative drugs, as illustrated by the launch of a generic version of Capoten. Capoten is an ACE inhibitor containing the active ingredient captopril. In November 2021, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, introduced the generic version known as Captopril. This medication is prescribed for conditions such as hypertension, congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack. Captopril is available in various dosage strengths (12.5 mg, 25 mg, 50 mg, and 100 mg) and is packaged in 100-count bottles.

In January 2023, AstraZeneca, a UK-based pharmaceutical company, made a significant acquisition by purchasing CinCor Pharma for $1.3 billion. This strategic move positions AstraZeneca to expand its product line of aldosterone synthase inhibitors (ASI), particularly for blood pressure lowering in the treatment of resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, specializes in developing novel treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. This acquisition aligns with AstraZeneca's overarching goal of diversifying its portfolio and addressing critical medical needs in the cardiovascular therapeutic area.

Major companies operating in the ace inhibitors market report are Pfizer Inc.,Novartis AG,Johnson & Johnson Private Limited, Merck KGaA,Sanofi S.A.,Bayer AG,United Therapeutics Corporation,Teva Pharmaceutical Industries Ltd.,Bristol-Myers Squibb Co.,Takeda Pharmaceuticals Company,Daiichi Sankyo Company Ltd.,UCB Schwarz Pharma Inc.,Solvay Pharmaceuticals B.V.,Endo International plc,Otto Brandes GmbH,Sun Pharmaceutical Industries Ltd.,Boehringer Ingelheim,Bausch Health Companies Inc.,Dr. Reddy's Laboratories,Abbott Laboratories,Eli Lilly and Company,Cipla Limited, GlaxoSmithKline plc,Cadila Healthcare Limited,AbbVie Inc., Mylan N.V., Sandoz Group AG,Accord Healthcare Ltd.,AstraZeneca plc,Lupin Limited,Macleods Pharmaceuticals Limited,Zydus lifescience Ltd.,Apotex Inc.

North America was the largest region in the ACE inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. ACE Inhibitors Market Characteristics

3. ACE Inhibitors Market Trends And Strategies

4. ACE Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global ACE Inhibitors Market Size and Growth

  • 5.1. Global ACE Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global ACE Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global ACE Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. ACE Inhibitors Market Segmentation

  • 6.1. Global ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Sulfhydryl-containing Agents
  • Dicarboxylate-containing Agents
  • Phosphonate-containing Agents
  • 6.2. Global ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ramipril
  • Enalapril
  • Benazepril
  • Fosinopril
  • Captopril
  • Moexipril
  • Other drugs
  • 6.3. Global ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral Tablets
  • Oral Solutions
  • 6.4. Global ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Diabetes
  • Heart Attack
  • Other Applications
  • 6.5. Global ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Online Drug Stores
  • Other End-Users

7. ACE Inhibitors Market Regional And Country Analysis

  • 7.1. Global ACE Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global ACE Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific ACE Inhibitors Market

  • 8.1. Asia-Pacific ACE Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China ACE Inhibitors Market

  • 9.1. China ACE Inhibitors Market Overview
  • 9.2. China ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India ACE Inhibitors Market

  • 10.1. India ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan ACE Inhibitors Market

  • 11.1. Japan ACE Inhibitors Market Overview
  • 11.2. Japan ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia ACE Inhibitors Market

  • 12.1. Australia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia ACE Inhibitors Market

  • 13.1. Indonesia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea ACE Inhibitors Market

  • 14.1. South Korea ACE Inhibitors Market Overview
  • 14.2. South Korea ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe ACE Inhibitors Market

  • 15.1. Western Europe ACE Inhibitors Market Overview
  • 15.2. Western Europe ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK ACE Inhibitors Market

  • 16.1. UK ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany ACE Inhibitors Market

  • 17.1. Germany ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France ACE Inhibitors Market

  • 18.1. France ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy ACE Inhibitors Market

  • 19.1. Italy ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain ACE Inhibitors Market

  • 20.1. Spain ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe ACE Inhibitors Market

  • 21.1. Eastern Europe ACE Inhibitors Market Overview
  • 21.2. Eastern Europe ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia ACE Inhibitors Market

  • 22.1. Russia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America ACE Inhibitors Market

  • 23.1. North America ACE Inhibitors Market Overview
  • 23.2. North America ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA ACE Inhibitors Market

  • 24.1. USA ACE Inhibitors Market Overview
  • 24.2. USA ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada ACE Inhibitors Market

  • 25.1. Canada ACE Inhibitors Market Overview
  • 25.2. Canada ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America ACE Inhibitors Market

  • 26.1. South America ACE Inhibitors Market Overview
  • 26.2. South America ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil ACE Inhibitors Market

  • 27.1. Brazil ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East ACE Inhibitors Market

  • 28.1. Middle East ACE Inhibitors Market Overview
  • 28.2. Middle East ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa ACE Inhibitors Market

  • 29.1. Africa ACE Inhibitors Market Overview
  • 29.2. Africa ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. ACE Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. ACE Inhibitors Market Competitive Landscape
  • 30.2. ACE Inhibitors Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson Private Limited
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck KGaA
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi S.A.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global ACE Inhibitors Market Competitive Benchmarking

32. Global ACE Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The ACE Inhibitors Market

34. ACE Inhibitors Market Future Outlook and Potential Analysis

  • 34.1 ACE Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 ACE Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 ACE Inhibitors Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer